However, with the emergence of results from the IMbrave150 study [90], atezolizumab (antiprogrammed death ligand 1) plus bevacizumab (anti‐VEGF) has received research interest not only for patients with unresectable HCC but also for those with resectable HCC at high risk of recurrence. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.